AR022251A1 - Antagonistas de factor de necrosis tumoral y uso de los mismos en endometrosis. - Google Patents

Antagonistas de factor de necrosis tumoral y uso de los mismos en endometrosis.

Info

Publication number
AR022251A1
AR022251A1 ARP000100108A ARP000100108A AR022251A1 AR 022251 A1 AR022251 A1 AR 022251A1 AR P000100108 A ARP000100108 A AR P000100108A AR P000100108 A ARP000100108 A AR P000100108A AR 022251 A1 AR022251 A1 AR 022251A1
Authority
AR
Argentina
Prior art keywords
antagonists
necrosis factor
tumor necrosis
endometrosis
infertility
Prior art date
Application number
ARP000100108A
Other languages
English (en)
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8237393&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR022251(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of AR022251A1 publication Critical patent/AR022251A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Los antagonistas de factor de necrosis tumoral son administrados en dosis terapéuticamente efectiva para tratar y/o prevenir endometriosis. Losantagonistas de esta invencion generalmente son seleccionados entre varias clases de moléculas, peroprefer entemente son receptores de TNF solubles. Losantagonistas son utiles para la regeneracion de lesiones endometrioticas y, si se combinan con otros ingredientes activos, para contrarrestrar afeccionesrelacionadas, tales como la infertilidad.
ARP000100108A 1999-01-22 2000-01-11 Antagonistas de factor de necrosis tumoral y uso de los mismos en endometrosis. AR022251A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99101194A EP1022027A1 (en) 1999-01-22 1999-01-22 Tumor necrosis factor antagonists and their use in endometriosis

Publications (1)

Publication Number Publication Date
AR022251A1 true AR022251A1 (es) 2002-09-04

Family

ID=8237393

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000100108A AR022251A1 (es) 1999-01-22 2000-01-11 Antagonistas de factor de necrosis tumoral y uso de los mismos en endometrosis.

Country Status (30)

Country Link
US (2) US6663865B1 (es)
EP (2) EP1022027A1 (es)
JP (1) JP4601176B2 (es)
KR (2) KR20060128056A (es)
CN (2) CN1212152C (es)
AR (1) AR022251A1 (es)
AT (1) ATE242002T1 (es)
AU (1) AU771964B2 (es)
BG (1) BG65556B1 (es)
BR (1) BR0008182A (es)
CA (1) CA2356737C (es)
CZ (1) CZ302866B6 (es)
DE (1) DE60003152T2 (es)
DK (1) DK1143997T3 (es)
EA (1) EA003927B1 (es)
EE (1) EE05543B1 (es)
ES (1) ES2200808T3 (es)
HK (2) HK1043059B (es)
HU (1) HU226149B1 (es)
IL (2) IL144413A0 (es)
NO (1) NO328814B1 (es)
NZ (1) NZ512585A (es)
PL (1) PL204713B1 (es)
PT (1) PT1143997E (es)
SI (1) SI1143997T1 (es)
SK (1) SK287313B6 (es)
TR (1) TR200102107T2 (es)
UA (1) UA78483C2 (es)
WO (1) WO2000043031A1 (es)
ZA (1) ZA200105263B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA010180B1 (ru) * 2001-01-29 2008-06-30 Лаборатуар Сероно Са Применение ингибитора il-18 для приготовления лекарственного средства для лечения и/или профилактики кардиомиопатии
US20050271663A1 (en) * 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
US20060073141A1 (en) * 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
EP1709965A3 (en) 2001-07-11 2006-12-27 Boehringer Ingelheim Pharmaceuticals, Inc. Methods of treating cytokine mediate diseases
US7082134B1 (en) * 2002-01-18 2006-07-25 Juniper Networks, Inc. Redirect checking in a network device
US20070298041A1 (en) * 2002-06-28 2007-12-27 Tomlinson Ian M Ligands That Enhance Endogenous Compounds
US9028822B2 (en) 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor
DE60325275D1 (de) * 2003-02-07 2009-01-22 Austria Wirtschaftsservice Gmbh Verwendung des menschlichen choriongonadotropins in der behandlung von endometriose-symptomen
CN102060806A (zh) 2003-09-11 2011-05-18 iTherX药品公司 细胞因子抑制剂
GB0327112D0 (en) 2003-11-21 2003-12-24 Clincial Designs Ltd Dispenser and reservoir
GB0408449D0 (en) 2004-04-15 2004-05-19 Banerjee Subhasis Diagnostic and therapeutic applications of soluble lhcge protein
US20080014172A1 (en) * 2004-05-28 2008-01-17 Applied Research Systems Ars Holding N.V. Use of Il-17 in the Treatment of Fertility-Related Disorders
US20060045902A1 (en) * 2004-09-01 2006-03-02 Serbousek Jon C Polymeric wrap for in vivo delivery of osteoinductive formulations
CN101282646B (zh) * 2005-07-12 2013-03-27 Dmi生物科学公司 治疗疾病的方法和产品
WO2008149147A2 (en) * 2007-06-06 2008-12-11 Domantis Limited Polypeptides, antibody variable domains and antagonists
AU2010264525B2 (en) * 2009-06-22 2015-04-02 Ampio Pharmaceuticals, Inc. Methods and products for treatment of diseases
PT2554174E (pt) * 2009-06-22 2015-12-15 Ampio Pharmaceuticals Inc Método para o tratamento de doenças
EA201500752A1 (ru) 2012-12-19 2016-05-31 Ампио Фармасьютикалс, Инк. Способ лечения заболеваний
WO2016140921A1 (en) 2015-03-02 2016-09-09 180 Therapeutics Lp Method of treating a localized fibrotic disorder using an il-33 antagonist

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5037805A (en) * 1989-03-20 1991-08-06 The Salk Institute For Biological Studies Methods of contraception
US20040120952A1 (en) * 2000-08-07 2004-06-24 Centocor, Inc Anti-TNF antibodies and peptides of human tumor necrosis factor
EP1681305A3 (en) * 1991-03-18 2008-02-27 New York University Monoclonal and chimeric antibodies specific for human tumor necrosis factor
CA2123593C (en) * 1992-09-15 2000-03-14 Craig A. Smith Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists
US5389657A (en) * 1993-02-01 1995-02-14 Free Radical Sciences Corporation Method for treating infertility
IL111125A0 (en) * 1994-05-11 1994-12-29 Yeda Res & Dev Soluble oligomeric tnf/ngf super family ligand receptors and their use
US5747532A (en) * 1995-11-21 1998-05-05 Medinox, Inc. Combinational therapeutic methods employing nitric oxide scavengers and compositions useful therefor
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US5710247A (en) * 1996-03-19 1998-01-20 Abbott Laboratories Process and intermediates for the synthesis of LHRH antagonists
GB9607120D0 (en) * 1996-04-04 1996-06-12 Chiroscience Ltd Compounds
GB9616643D0 (en) * 1996-08-08 1996-09-25 Chiroscience Ltd Compounds
ATE429241T1 (de) * 1996-11-27 2009-05-15 Immunex Corp Verfahren zur regulierung der stickstoffmonoxid- erzeugung
US6514977B1 (en) * 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors

Also Published As

Publication number Publication date
BR0008182A (pt) 2001-11-06
SK287313B6 (sk) 2010-06-07
EP1143997B1 (en) 2003-06-04
EA003927B1 (ru) 2003-10-30
US20040057954A1 (en) 2004-03-25
KR20060128056A (ko) 2006-12-13
NO20013577D0 (no) 2001-07-19
CA2356737A1 (en) 2000-07-27
WO2000043031A1 (en) 2000-07-27
PL204713B1 (pl) 2010-02-26
JP2002535284A (ja) 2002-10-22
JP4601176B2 (ja) 2010-12-22
CN1698894A (zh) 2005-11-23
CN1212152C (zh) 2005-07-27
HK1082690A1 (en) 2006-06-16
HK1043059A1 (en) 2002-09-06
CZ302866B6 (cs) 2011-12-21
PL350002A1 (en) 2002-10-21
EP1022027A1 (en) 2000-07-26
IL144413A0 (en) 2002-05-23
CA2356737C (en) 2010-03-23
PT1143997E (pt) 2003-10-31
BG105691A (en) 2002-02-28
KR20010101397A (ko) 2001-11-14
NO20013577L (no) 2001-08-29
EE05543B1 (et) 2012-06-15
TR200102107T2 (tr) 2001-12-21
BG65556B1 (bg) 2008-12-30
ES2200808T3 (es) 2004-03-16
AU771964B2 (en) 2004-04-08
DE60003152T2 (de) 2004-03-25
EA200100799A1 (ru) 2001-12-24
ZA200105263B (en) 2002-06-26
HK1043059B (zh) 2005-11-18
DE60003152D1 (de) 2003-07-10
HU226149B1 (en) 2008-05-28
IL144413A (en) 2009-05-04
SI1143997T1 (en) 2003-12-31
CZ20012656A3 (cs) 2002-02-13
CN1337883A (zh) 2002-02-27
CN100594932C (zh) 2010-03-24
EP1143997A1 (en) 2001-10-17
SK10292001A3 (sk) 2001-12-03
UA78483C2 (en) 2007-04-10
NO328814B1 (no) 2010-05-18
US6663865B1 (en) 2003-12-16
ATE242002T1 (de) 2003-06-15
KR100685106B1 (ko) 2007-02-22
EE200100378A (et) 2002-10-15
AU1997300A (en) 2000-08-07
NZ512585A (en) 2003-08-29
HUP0105103A3 (en) 2004-08-30
DK1143997T3 (da) 2003-09-15
HUP0105103A2 (hu) 2002-04-29

Similar Documents

Publication Publication Date Title
AR022251A1 (es) Antagonistas de factor de necrosis tumoral y uso de los mismos en endometrosis.
BR0112311A (pt) Compostos e composições para liberar agentes ativos, forma de dosagem unitária, método para preparar ditas composições e seu uso
IL132661A0 (en) Agonists specific for the peripheral cannabinoid receptor
MXPA02005602A (es) Compuestos de urea que tienen actividad antagonista para el receptor muscarinico.
UY26482A1 (es) Bifenil sulfonamidas como antagonistas de receptores de angiotensina endotelina duales
IL140622A0 (en) Biphenyl sufonamide derivatives, pharmaceutical compositions containing the same and methods for the preparation thereof
BR9706934A (pt) Novos compostos de imidazol substituìdo
GT200300294A (es) Compuestos de indazol y composiciones farmaceuticas para inhibir proteinquinasas y procedimientos para su uso
ES2377720T3 (es) Anticuerpos monoclonales agon�?sticos epha2 y métodos de uso de los mismos.
PT1054887E (pt) Derivados biciclicos de piridina e pirimidina como antagonistas de receptores no neuropeptido y
MXPA01008611A (es) Compuestos y composiciones para suministrar agentes activos.
PA8637601A1 (es) Compuestos moduladores de la actividad de c-kit y usos de los mismos
PL347671A1 (en) Compounds and compositions for delivering active agents
GT199900189A (es) Agonistas de receptores 5-ht1 y metoclopramida para el tratamiento de la migraña.
ATE303804T1 (de) Behandlung von sexueller funktionsstörung mit bombesin rezeptor antagonisten
SE9900961D0 (sv) Novel compounds
CA2325842A1 (en) Methods for making and delivering rho-antagonist tissue adhesive formulations to the injured mammalian central and peripheral nervous systems and uses thereof
BR9909486A (pt) Compostos calcilìticos
TR200200066T2 (tr) Migrenin tedavisi için seçici iGluR5 reseptör antagonistleri
TR200200359T2 (tr) Cgrp Antagonist'lerinin ve cgrp-release (Gevşeme)-Engelleyici Menopoza Bağlı Deri Kızarıklıklarında Kullanılması
BRPI0507987A (pt) métodos e compostos moduladores receptor de glicocorticóide
DE69819742D1 (de) Indolderivate als 5-ht1b und 5-ht1d agonisten
WO2002056903A3 (en) Methods for treating hormone associated conditions using a combination of lhrh antagonists and specific estrogen receptor modulators
CO5200773A1 (es) Mesoprogestinas (moduladores de receptores para progestero- na) como componente de composiciones utilizadas para la terapia de sustitucion hormonal (trh)
AR018825A1 (es) Antagonistas del receptor de bradiquinina no peptidica para uso en el tratamiento de trastornos y enfermedades oftalmicas

Legal Events

Date Code Title Description
FB Suspension of granting procedure